Cold Spring Venture Advisors

Providing product and clinical development and strategic advisory services to life science companies.

Principal

Aldeyra Therapeutics

Clinical stage company developing novel compounds to target aldehydes implicated in the pathogenesis of inflammatory conditions and orphan diseases; (NASDAQ:ALDX)

Member, Board of Directors (Chair, Nominating & Governance Committee; member, Audit Committee)

Cleveland Diagnostics, Inc.

Developer of cancer diagnostics based on protein structural vartiability as detected by solvent interaction analysis

Chairman, Board of Directors

Short Wave Pharma

Short Wave Pharma Inc. is an Israel-based biopharmaceutical company developing novel
formulations of psilocybin combined with additional APIs and customized delivery methods to
provide significant medical benefits for patients suffering from mental health disorders,
neurodegenerative diseases, chronic pain, and potentially other medical conditions where
psilocybin is known to have a positive effect.

1CellBio Inc.

1CellBiO Inc. is a leading single-cell analysis company commercializing the open, flexible and cost-effective inDropTM instrument for single cell, high resolution whole transcriptome profiling with unparalleled data quality.

Member Board Of Directors

Weill Cornell Medicine

Visiting Assistant Professor of Pathology and Laboratory Medicine

Member, Scientific Advisory Committee, Daedalus Fund for Innovation

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology.  Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist.

Executive Vice President, Clinical Development

Sentien Biotechnologies, Inc.

Sentien's lead product, the Sentinel™, will actively treat acute kidney injury (acute renal failure) patients during continuous renal replacement therapy by supplementing patient blood with Mesenchymal Stromal Cell-derived secretions, a mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repair response. The company has developed proprietary Mesenchymal Stromal Cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy.

Chief Medical Officer (interim)

Cytrellis Biosystems, Inc.

Cytrellis is a clinical stage company developing a new class of aesthetic medical devices

Senior Clinical Advisor

Stealth BioTherapeutics

Developing therapeutics for mitochondrial diseases

Taplio

Ben Bronstein, MD's Linkedin Analytics

Ben Bronstein, MD

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Ben Bronstein, MD's Linkedin Analytics

Ben Bronstein, MD

Want to drive more opportunities from LinkedIn?

Ben Bronstein, MD's Linkedin Analytics